Scientific Rationale and Primary Endpoint Achievement in the ALKIVIA Phase 3 Trial

argenx's novel neonatal Fc receptor (FcRn) targeted therapy, Vyvgart Hytrulo (containing efgartigimod alfa and hyaluronidase-qvfc), has successfully met the primary endpoint in the ALKIVIA global Phase 2/3 trial, which evaluated patients with autoimmune myositis. In this trial, the Vyvgart Hytrulo arm demonstrated a statistically significant improvement in the Total Improvement Score (TIS) at week 52, with a mean difference of 15.4 points compared to the placebo arm (p=0.0011). This is particularly significant as it offers a new therapeutic option for patients suffering from muscle weakness and muscle destruction, potentially reducing their dependence on steroids, and holds considerable clinical significance.

Efficacy Analysis by Subtype - Success in IMNM, Limitations in DM, and Regulatory Approval Prospects

The success of this trial was driven by the robust efficacy data observed in the immune-mediated necrotizing myopathy (IMNM) patient population, one of the two myositis subtypes for which there was previously no effective treatment. In the IMNM group, a statistically significant improvement in TIS of 14.8 points was demonstrated compared to placebo (p=0.0048), making it the first targeted therapy to demonstrate statistical significance in a Phase 3 clinical trial. While the dermatomyositis (DM) group showed a substantial improvement of 14.5 points, statistical significance was not achieved due to a limited number of patients (p=0.1093). Nevertheless, industry analysts anticipate that, following prior discussions with the U.S. Food and Drug Administration (FDA), argenx may be able to pursue approval for both subtypes, either without additional clinical trials or with minimal data supplementation.

Commercial Value of the Vyvgart Franchise and Diversification of Revenue Streams

Vyvgart is already approved for the treatment of generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and has grown argenx into a large biotechnology company with a market capitalization exceeding $60 billion. Vyvgart has demonstrated strong growth, generating approximately $2.9 billion in revenue in the first half of 2026 alone, and the expansion of its indication to the myositis market is expected to be a new driver of revenue growth. This success in the ALKIVIA trial has quickly reversed the decline in pipeline value that had occurred following failures in previous clinical trials for pemphigus and Thyroid Eye Disease.

Competitive Landscape in the Myositis Treatment Market and argenx's First-Mover Advantage

The global market for dermatomyositis and myositis treatments is currently estimated at approximately $2.8 billion in 2025 and is projected to grow rapidly to approximately $5.4 billion by 2034, with an annual growth rate of 7.8%. The current market offers limited treatment options, such as Octapharma's intravenous immunoglobulin (IVIG) product, Octagam 10%. Notably, there are currently no approved targeted biologic therapies for IMNM. If argenx is able to obtain approval for Vyvgart Hytrulo as the first targeted therapy for IMNM, it will undoubtedly gain a significant first-mover advantage over competitors such as UCB's Rystiggo and Johnson & Johnson's nipocalimab, which are also developing FcRn inhibitors.